Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Current Deferred Revenue (2020 - 2025)

SOPHiA GENETICS's Current Deferred Revenue history spans 6 years, with the latest figure at $16.7 million for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue rose 191.7% to $16.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.7 million, a 191.7% increase, with the full-year FY2025 number at $16.7 million, up 191.7% from a year prior.
  • Current Deferred Revenue hit $16.7 million in Q4 2025 for SOPHiA GENETICS, up from $10.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for SOPH hit a ceiling of $16.7 million in Q4 2025 and a floor of $3.4 million in Q4 2022.
  • Historically, Current Deferred Revenue has averaged $7.4 million across 5 years, with a median of $7.7 million in 2023.
  • Biggest five-year swings in Current Deferred Revenue: plummeted 39.63% in 2024 and later surged 191.7% in 2025.
  • Tracing SOPH's Current Deferred Revenue over 5 years: stood at $4.1 million in 2021, then fell by 15.61% to $3.4 million in 2022, then soared by 176.47% to $9.5 million in 2023, then plummeted by 39.63% to $5.7 million in 2024, then soared by 191.7% to $16.7 million in 2025.
  • Business Quant data shows Current Deferred Revenue for SOPH at $16.7 million in Q4 2025, $10.0 million in Q3 2025, and $9.6 million in Q2 2025.